IFRX InflaRx: Multiplikator Forward P/S

The projected P/S multiple for InflaRx N.V. (IFRX) exhibits volatility, with the 386.20 level capturing the current state. This trend is driven by German laboratories and external antibody production. An outsourcing strategy for research minimizes capital expenditures while ensuring team flexibility. Prospects depend on the expansion of the drug Gohibic into intensive care units, although regulators are slowing the growth of the clinic network with post-audit requirements.

InflaRx N.V. develops high-tech antibodies to prevent systemic immune destruction of organs, making its market capitalization dependent on commercialization forecasts. By analyzing the expected price-to-sales ratio, an investor assesses the current share price relative to future sales, determining the degree of optimism currently priced in and the resilience of the market valuation to potential corrections should growth rates shift.